legacyFXofficial

JNJ bullish scenario:

Long
NYSE:JNJ   Johnson & Johnson
The technical figure Pennant can be found in the US company Johnson & Johnson (JNJ) at daily chart. Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. The Pennant has broken through the resistance line on 23/05/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 6 days towards 184.37 USD. Your stop loss order according to experts should be placed at 172.71 USD if you decide to enter this position.

Johnson & Johnson is now working to spin off its consumer health division and after the company entered a series of settlements for its part in the opioid crisis. First-quarter metrics were mixed, but the company's medical devices business had few declines.

Now, the Dow index stalwart expects $94.8 billion to $95.8 billion in 2022 sales. That no longer includes prior expectations for $3 billion to $3.5 billion in Covid vaccine sales.

Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.